pneumonia in adult patients with COPD similar to the control event rate in the trial population of the TORCH Study,38 the annualized number needed to harm for serious pneumonia associated with inhaled corticosteroid use added to long-acting β-agonist therapy is estimated to be 47 (95% CI, 34...
LAMA-LABAs were associated with a lower hazard of first moderate or severe COPD exacerbation (HR, 0.91; 95% CI, 0.86-0.96) and a lower hazard of first pneumonia hospitalization (HR, 0.75; 95% CI, 0.69-0.83) compared with Advair Diskus and a lower hazard of first moderate or severe COPD...
The lung wedge biopsy on day 34 of disease onset has demonstrated a triplet findings of respiratory cell injury, vascular damage and fibrosis, similar to previously reported COVID19 lung pathology [12]. However, the lung wedge biopsy in our case showed numerous neutrophilic infiltration, which has...
LTRAs and LAMAs (tiotropium) in paediatric patients aged 4–17 years with asthma35. LABA treatment as add-on to ICS improved lung function when compared with placebo, as measured by FEV1and FEV1% predicted. There was no difference in risk of exacerbations requiring oral corticosteroid (OCS...
ICS/LABA combination agents combine corticosteroids and long-acting bronchodilators. Fluticasone/salmeterol (Advair, AirDuo, Wixela), budesonide/formoterol (Symbicort), fluticasone/vilanterol (Breo), mometasone/formoterol (Dulera). Leukotriene modifiers (montelukast[Singulair],zafirlukast[Accolate],zileuton[Zy...
ICS/LABA combination agents combine corticosteroids and long-acting bronchodilators. Fluticasone/salmeterol (Advair, AirDuo, Wixela), budesonide/formoterol (Symbicort), fluticasone/vilanterol (Breo), mometasone/formoterol (Dulera). Leukotriene modifiers (montelukast[Singulair],zafirlukast[Accolate],zileuton[Zy...
ICS/LABA combination agents combine corticosteroids and long-acting bronchodilators. Fluticasone/salmeterol (Advair, AirDuo, Wixela), budesonide/formoterol (Symbicort), fluticasone/vilanterol (Breo), mometasone/formoterol (Dulera). Leukotriene modifiers (montelukast[Singulair],zafirlukast[Accolate],zileuton[Zy...
ICS/LABA combination agents combine corticosteroids and long-acting bronchodilators. Fluticasone/salmeterol (Advair, AirDuo, Wixela), budesonide/formoterol (Symbicort), fluticasone/vilanterol (Breo), mometasone/formoterol (Dulera). Leukotriene modifiers (montelukast[Singulair],zafirlukast[Accolate],zileuton[Zy...
ICS/LABA combination agents combine corticosteroids and long-acting bronchodilators. Fluticasone/salmeterol (Advair, AirDuo, Wixela), budesonide/formoterol (Symbicort), fluticasone/vilanterol (Breo), mometasone/formoterol (Dulera). Leukotriene modifiers (montelukast[Singulair],zafirlukast[Accolate],zileuton[Zy...
ICS/LABA combination agents combine corticosteroids and long-acting bronchodilators. Fluticasone/salmeterol (Advair, AirDuo, Wixela), budesonide/formoterol (Symbicort), fluticasone/vilanterol (Breo), mometasone/formoterol (Dulera). Leukotriene modifiers (montelukast[Singulair],zafirlukast[Accolate],zileuton[Zy...